NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues
- CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter 2025 for the period ended March 31, 2025.
- 05/12/2025
|
NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025
- Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern Time Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern Time
- 05/05/2025
|
NeurAxis Stock Gains Post Q4 Earnings and Revenue Growth
- NRXS records strong revenue growth, expanded insurance coverage and new FDA clearances in fourth-quarter 2024.
- 03/24/2025
|
NeurAxis, Inc. (NRXS) Q4 2024 Earnings Call Transcript
- NeurAxis, Inc. (NYSE:NRXS ) Q4 2024 Earnings Conference Call March 20, 2025 9:00 AM ET Company Participants Ben Shamsian - Investor Relations Brian Carrico - Chief Executive Officer Tim Henrichs - Chief Financial Officer Operator Good day, and thank you for standing by. Welcome to the NeurAxis' Fourth Quarter 2024 Financial Results Conference Call.
- 03/20/2025
|
NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues
- CARMEL, Ind., March 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter and fiscal year 2024 for the period ended December 31, 2024.
- 03/20/2025
|
NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025
- CARMEL, Ind., March 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its fourth quarter and fiscal year 2024, for the period ended December 31, 2024, on Thursday, March 20, 2025, before market open. The Company has scheduled a conference call for the same day, Thursday, March 20, 2025, at 9:00 am ET to review the results.
- 03/12/2025
|
UPDATE - NeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States
- CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), with a prominent insurer, with approximately 5.1 million members across 13 states.
- 01/21/2025
|
NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States
- CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), with Molina Healthcare. Molina, with over 40 years in operation, has approximately 5.1 million members across 13 states.
- 01/21/2025
|
NeurAxis Inc. Issues Letter to Shareholders
- CARMEL, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that CEO Brian Carrico has published a letter to shareholders highlighting the Company's achievements in 2024 and vision for 2025.
- 01/13/2025
|
NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
- CARMEL, Ind., Jan. 06, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that CEO Brian Carrico will participate in a webcasted company presentation at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.
- 01/06/2025
|
NeurAxis, Inc (NRXS) Q3 2024 Earnings Call Transcript
- NeurAxis, Inc (NYSE:NRXS ) Q3 2024 Results Conference Call November 12, 2024 9:00 AM ET Company Participants Ben Shamsian - Investor Relations Brian Carrico - Chief Executive Officer Tim Henrichs - Chief Financial Officer Operator Good day, and thank you for standing by. Welcome to the NeurAxis's Third Quarter 2024 Financial Results Conference Call.
- 11/15/2024
|
NeurAxis Stock Surges After Strong Q3 Earnings and Expanded Coverage
- NRXS reports strong third-quarter results with rising revenues, reduced losses and expanded insurance coverage, driving its stock to outperform the market.
- 11/15/2024
|
NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues
- Conference call will be held today, Tuesday, November 12 at 9:00 am ET Conference call will be held today, Tuesday, November 12 at 9:00 am ET
- 11/12/2024
|
NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation
- CARMEL, Ind., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, announced that the American Medical Association (AMA) has established a new Current Procedural Terminology (CPT) Category I code for Percutaneous Electrical Nerve Field Stimulation (PENFS) procedures effective January 1, 2026.
- 10/22/2024
|
Zacks Initiates Coverage of NeurAxis With Neutral Recommendation
- Discover why Zacks rates NeurAxis as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore NRXS' promising growth prospects and financial health amid market challenges.
- 09/25/2024
|
NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
- CARMEL, Ind., Sept. 19, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference, taking place virtually on Tuesday, October 1, 2024.
- 09/19/2024
|
NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024
- CARMEL, Ind., Aug. 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), for Geisinger Health Plan, serving 600,000+ enrollees in central Pennsylvania. This medical policy will bring our national total coverage for PENFS to roughly 24 million insured lives, with more decisions from major payers still pending.
- 08/27/2024
|
NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024
- CARMEL, Ind., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), for Blue Cross Blue Shield (BCBS) of Vermont Medical Members, effective 10/1/2024. This medical policy will bring our national total coverage for PENFS to roughly 23 million, with more decisions from major payers still pending.
- 08/13/2024
|
NeurAxis, Inc. (NRXS) Q2 2024 Earnings Call Transcript
- NeurAxis, Inc. (NYSE:NRXS ) Q2 2024 Earnings Conference Call August 9, 2024 9:00 AM ET Company Participants Ben Shamsian - Investor Relations Brian Carrico - Chief Executive Officer Tim Henrichs - Chief Financial Officer Conference Call Participants Mark Foster - Kirr Marbach & Co Operator Good day and thank you for standing by. Welcome to NeurAxis Reports Second Quarter 2024 Financial Results.
- 08/11/2024
|
NeurAxis Reports Second Quarter 2024 Financial Results
- Carmel, Ind., Aug. 09, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the second quarter period ended June 30, 2024.
- 08/09/2024
|
NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure
- CARMEL, Ind., June 07, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced a submission to the FDA for expansion of its IB-Stim label. The new submission is significant as it would allow access to a larger patient population beyond 11-18 years of age and allow for marketing of 4 devices per prescription.
- 06/07/2024
|
NeurAxis, Inc. (NRXS) Q1 2024 Earnings Call Transcript
- NeurAxis, Inc. (NYSE:NRXS ) Q1 2024 Earnings Conference Call May 22, 2024 9:00 AM ET Company Participants Ben Shamsian - Investor Relations Brian Carrico - Chief Executive Officer Tim Henrichs - Chief Financial Officer Operator Good day, and thank you for standing by. Welcome to NeurAxis Reports First Quarter 2024 Financial Results.
- 05/22/2024
|
NeurAxis Reports First Quarter 2024 Financial Results
- CARMEL, Ind., May 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter 2024 for the period ended March 31, 2024.
- 05/22/2024
|
NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
- CARMEL, Ind., May 21, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.
- 05/21/2024
|
NeurAxis to Host First Quarter 2024 Results and Business Update Call on Wednesday, May 22, 2024
- CARMEL, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its first quarter 2024, for the period ended March 31, 2024, on Wednesday, May 22, 2024, before market open. The Company has scheduled a conference call for the same day, Wednesday, May 22, 2024, at 9:00 am ET to review the results.
- 05/15/2024
|
NeurAxis Announces New Medical Policy Coverage in North Dakota
- CARMEL, Ind., April 23, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the publication of medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), effective 05/06/2024, with a Blue Cross Blue Shield (BCBS) licensee in North Dakota. The BCBS licensee is the largest provider of health care coverage in North Dakota, insuring and/or administering claims for over 310,000 people, effective May 6, 2024.
- 04/23/2024
|
NeurAxis, Inc. (NRXS) Q4 2023 Earnings Call Transcript
- NeurAxis, Inc. (NYSE:NRXS ) Q4 2023 Earnings Call Transcript April 9, 2024 4:30 PM ET Company Participants Ben Shamsian - IR, Lytham Partners Brian Carrico - CEO Tim Henrichs - CFO Operator Thank you for standing by and welcome to NeurAxis Fourth Quarter and Fiscal Year 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
- 04/09/2024
|
NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
- CARMEL, Ind., April 09, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter and fiscal year 2023 for the period ended December 31, 2023.
- 04/09/2024
|
NeurAxis to Host Fourth Quarter and Full Year 2023 Results and Business Update Call on Tuesday, April 9, 2024
- CARMEL, Ind., April 01, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its fourth quarter and fiscal year 2023, for the period ended December 31, 2023, on Tuesday, April 9, 2024, after the close of the market. The Company has scheduled a conference call for the same day, Tuesday, April 9, 2024, at 4:30 pm ET to review the results.
- 04/01/2024
|
NeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center Registry
- CARMEL, Ind., March 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the results of a multicenter registry study on IB-Stim for pediatric disorders of gut-brain interaction (DGBI). IB-Stim is NeurAxis' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology therapy. The large and comprehensive study concluded efficacy of IB-Stim for gastrointestinal symptoms and functionality for pediatric disorders of gut-brain interaction (DGBI).
- 03/27/2024
|
NeurAxis Announces Highmark BCBS Policy Coverage
- CARMEL, Ind., March 11, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced receipt of Highmark Blue Cross Blue Shield (“Highmark BCBS”) policy coverage for approximately seven million lives effective April 8, 2024. Highmark BCBS provides coverage in the mid-Atlantic, covering Pennsylvania, Delaware, New York, and West Virginia.
- 03/11/2024
|
NeurAxis Announces Blue Cross and Blue Shield of Kansas City Policy Coverage
- CARMEL, Ind., March 04, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced receipt of Blue Cross and Blue Shield of Kansas City (“BCBSKC”) policy coverage for approximately one million lives. BCBSKC provides coverage in the Kansas City, Missouri metropolitan areas including Johnson and Wyandotte counties in Kansas.
- 03/04/2024
|
NeurAxis to Present at Oppenheimer 34th Annual Healthcare MedTech & Services Conference
- CARMEL, Ind., Feb. 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced that President and Chief Executive Officer Brian Carrico and Chief Medical Officer Dr. Adrian Miranda, will participate in the upcoming Oppenheimer 34th Annual Healthcare MedTech & Services Conference on March 12, 2024.
- 02/27/2024
|
NeurAxis Appoints Timothy Henrichs as Chief Financial Officer
- CARMEL, Ind., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the appointment of Timothy Henrichs as Chief Financial Officer (CFO), effective February 5, 2024. As part of his appointment, Mr. Henrichs has resigned as an independent director on the board of NeurAxis (the “Board”).
- 01/31/2024
|
NeurAxis, Inc. Issues Letter to Shareholders from Brian Carrico, President and Chief Executive Officer
- CARMEL, Ind., Dec. 20, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today issued a letter to its shareholders.
- 12/20/2023
|
NeurAxis Reports Third Quarter 2023 Financial Results
- CARMEL, Ind., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today reported financial results for the third quarter ended September 30, 2023.
- 11/20/2023
|
NeurAxis Announces CareFirst BCBS Policy Coverage
- CARMEL, Ind., Nov. 15, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced receipt of CareFirst Blue Cross Blue Shield (“CareFirst BCBS”) policy coverage for the mid-Atlantic region with 3.5 million lives. CareFirst BCBS is the largest healthcare insurer in the mid-Atlantic that includes Maryland, Washington DC, and Northern Virginia.
- 11/15/2023
|
NeurAxis Secures $3 Million Financing
- CARMEL, Ind., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced it has secured a $3 million financing for NeurAxis through a preferred stock offering priced at $2.38 per share.
- 11/14/2023
|
NeurAxis Signs Exclusive Option Agreement with University of Michigan for Innovative Gastrointestinal Device
- CARMEL, Ind., Nov. 08, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced it has executed an exclusive option agreement with the University of Michigan for the exclusive licensing of its innovative rectal expulsion device (RED). The RED redesigns the balloon expulsion testing workflow to directly simplify anorectal function testing downstream to any gastroenterologist's office. During the option agreement period, NeurAxis intends to evaluate the vast market potential for RED.
- 11/08/2023
|
NeurAxis Reports Second Quarter 2023 Financial Results
- CARMEL, Ind., Sept. 21, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today reported financial results for the second quarter ended June 30, 2023.
- 09/21/2023
|
NeurAxis to Present at the Gilmartin Group Emerging Growth Showcase
- CARMEL, Ind., Sept. 13, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced that President and Chief Executive Officer Brian Carrico and Chief Medical Officer Dr. Adrian Miranda, will present at the upcoming Gilmartin Group Emerging Growth Showcase on Thursday, September 21, 2023, at 9:00 am ET.
- 09/13/2023
|
NeurAxis Announces Publication of Prospective Study Showing IB-Stim™ Improves Quality of Life of Adolescents with IBS
- CARMEL, Ind., Sept. 12, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the publication of Prospective study of the effect of auricular percutaneous electrical nerve field stimulation on quality of life in children with pain related disorders of gut-brain interaction, a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of IB-Stim™ in children with post-concussion symptoms, featured in the September 2023 Frontiers in Pain Research.
- 09/12/2023
|
NeurAxis Highlights Pediatric Post-Concussion Clinical Study
- CARMEL, Ind., Aug. 29, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlighted A Prospective Study on the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS™) in Patients with Post-Concussion Syndrome (PCS), a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of IB-Stim™ in children with post-concussion symptoms.
- 08/29/2023
|
NeurAxis Highlights Strength of its Board of Directors
- CARMEL, Ind., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlighted the strength of its board of directors.
- 08/24/2023
|
U.S. IPO Weekly Recap: IPO Market Sees Fitness, Liquor Marketing, And Medical Devices
- Three small issuers began trading this past week, two of which were eligible for inclusion in our IPO stats. While most IPOs are biding their time through the August break, the SPAC market is churning out deals. Three IPOs are currently scheduled to list in the week ahead, although other small issuers may join the calendar during the week.
- 08/12/2023
|
U.S. IPO Weekly Recap: July Closes Out With 2023's First Direct Listing And A Wave Of Small IPOs
- U.S. IPO Weekly Recap: July Closes Out With 2023's First Direct Listing And A Wave Of Small IPOs
- 07/29/2023
|
Medtech company NeurAxis upsizes IPO and lowers price to $6 a share vs. $8 previously
- NeurAxis, a medical technology company with an FDA-approved therapy to treat abdominal pain associated with IBS in adolescents aged 11 to 18 years old, tweaked the terms of its initial public offering on Friday. In a filing with the Securities and Exchange Commission, the company said it now plans to offer 1.7 million shares priced at $6 each, while selling shareholders will offer 2.8 million shares.
- 07/21/2023
|
Neuraxis Seeks $15 Million IPO For Device Expansion
- Neuraxis, Inc. has filed proposed terms for a $15 million U.S. IPO. The firm is developing neuromodulation technologies for the treatment of various pediatric digestive and nausea conditions.
- 01/27/2023
|
Neuraxis Begins $33 Million U.S. IPO Effort
- Neuraxis has filed to raise $33 million in a U.S. IPO, although the final figure may differ. The company is developing and commercializing neurostimulation treatments for irritable bowel syndrome and other health conditions.
- 01/12/2023
|
